<?xml version='1.0' encoding='utf-8'?>
<document id="27045668"><sentence text="Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: Physiological role of enzymes and transporters."><entity charOffset="35-43" id="DDI-PubMed.27045668.s1.e0" text="bosentan" /></sentence><sentence text="Bosentan, an endothelin-1 (ET) receptor antagonist is an important drug for the effective management of patients with pulmonary arterial hypertension"><entity charOffset="0-8" id="DDI-PubMed.27045668.s2.e0" text="Bosentan" /></sentence><sentence text=" Bosentan has a rather complicated pharmacokinetics in humans involving multiple physiological components that have a profound influence on its drug disposition"><entity charOffset="1-9" id="DDI-PubMed.27045668.s3.e0" text="Bosentan" /></sentence><sentence text=" Bosentan is mainly metabolized by cytochrome P450 (CYP) 3A4 and 2C9 enzymes with the involvement of multiple transporters that control its hepatic uptake and biliary excretion"><entity charOffset="1-9" id="DDI-PubMed.27045668.s4.e0" text="Bosentan" /></sentence><sentence text=" The involvement of phase 2 metabolism of bosentan is a key to have an enhanced biliary excretion of the drug-related products"><entity charOffset="42-50" id="DDI-PubMed.27045668.s5.e0" text="bosentan" /></sentence><sentence text=" While bosentan exhibits high protein binding restricting the drug from extensive distribution and significant urinary excretion, bosentan induces its own metabolism by an increased expression of CYP3A4 on repeated dosing"><entity charOffset="7-15" id="DDI-PubMed.27045668.s6.e0" text="bosentan" /><entity charOffset="130-138" id="DDI-PubMed.27045668.s6.e1" text="bosentan" /><pair ddi="false" e1="DDI-PubMed.27045668.s6.e0" e2="DDI-PubMed.27045668.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27045668.s6.e0" e2="DDI-PubMed.27045668.s6.e1" /></sentence><sentence text=" Due to the above properties, bosentan has the potential to display drug-drug interaction with the co-administered drugs, either being a perpetrator or a victim"><entity charOffset="30-38" id="DDI-PubMed.27045668.s7.e0" text="bosentan" /></sentence><sentence text=" The intent of this review is manifold: a) to summarize the physiological role of CYP enzymes and hepatic-biliary transporters; b) to discuss the mechanism(s) involved in the purported liver injury caused by bosentan; c) to tabulate the numerous clinical drug-drug interaction studies involving the physiological interplay with CYP and/or transporters; d) to provide some perspectives on dosing strategy of bosentan"><entity charOffset="208-216" id="DDI-PubMed.27045668.s8.e0" text="bosentan" /><entity charOffset="407-415" id="DDI-PubMed.27045668.s8.e1" text="bosentan" /><pair ddi="false" e1="DDI-PubMed.27045668.s8.e0" e2="DDI-PubMed.27045668.s8.e0" /><pair ddi="false" e1="DDI-PubMed.27045668.s8.e0" e2="DDI-PubMed.27045668.s8.e1" /></sentence><sentence text=" " /></document>